The Technical Analyst
CONX Corp. [CONX]
Exchange: NASDAQ Sector: Financial Services Industry: Shell Companies
CONX Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.38% $10.56
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 220.39 mill |
| EPS: | -0.250 |
| P/E: | -42.24 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 20.87 mill |
| Avg Daily Volume: | 0.0027 mill |
| RATING 2024-04-25 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -42.24 | sector: PE -18.15 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -42.24 | industry: PE -25.74 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0883 (-100.84%) $-10.65 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 10.45 - 10.67 ( +/- 1.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-02 | Jericho Capital Asset Management L.p. | Sell | 4 000 000 | Class A Common Stock, par value $0.0001 per share |
| 2023-03-01 | Jericho Capital Asset Management L.p. | Buy | 0 | Class A Common Stock, par value $0.0001 per share |
| 2022-10-31 | Moore Capital Management, Lp | Buy | 0 | Class A Common Stock |
| 2021-10-29 | Moskowitz David K | Sell | 0 | Class A Common Stock |
| 2021-01-27 | Steckel Adrian | Sell | 0 | Class A Common Stock |
| INSIDER POWER |
|---|
| -100.00 |
| Last 4 transactions |
| Buy: 0 | Sell: 6 812 500 |
Forecast:
16:00 - $10.56
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $10.56 (-0.38% ) |
| Volume | 0.0006 mill |
| Avg. Vol. | 0.0027 mill |
| % of Avg. Vol | 23.07 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CONX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CONX
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
Last 10 Buy Signals
Latest Press Releases
2024-04-15 18:00:00 - Press Release
Conx Corp. Announces Change In Tender Offer Price To Complete Business Combination
Littleton, colo. , april 15, 2024 /prnewswire/ -- conx corp. (nasdaq: conx) (the "company" or "conx") announced today that it has changed the price to be paid in its previously announced tender offer (the "tender offer") to purchase up to 2,120,269 of its shares of class a common stock, par value $0.0001 per share (the "class a common stock"), to $10.598120 per share (the "purchase price").
2024-04-01 16:30:00 - Press Release
Conx Corp. Announces Tender Offer To Complete Business Combination
Littleton, colo. , april 1, 2024 /prnewswire/ -- conx corp. (nasdaq: conx) (the "company" or "conx") announced today that it has commenced a tender offer (the "tender offer") to purchase up to 2,120,269 of its shares of class a common stock, par value $0.0001 per share (the "class a common stock"), at a purchase price of $10.585614 per share (the "purchase price").
2022-10-12 20:00:00 - Press Release
Conx Files Proxy Statement For Stockholders To Vote On Extension Of Completion Period; Discloses Preliminary Discussions Regarding Business Combination
Littleton, colo. , oct. 12, 2022 /prnewswire/ -- conx, corp. (nasdaq: conx, conxu, conxw) ("conx" or the "company") encourages stockholders to vote in favor of the proposal to amend conx's articles of incorporation (the "extension amendment") to extend the date by which the company must complete a business combination from november 3, 2022 to june 3, 2023 (the "extension").
2015-02-26 09:15:00 - Press Release
Corgenix Receives Fda Authorization And Who Listing For Emergency Use
Of Ebola Rapid Diagnostic Test
Denver--(business wire)--corgenix medical corporation (otcqb: conx), a worldwide developer and marketer of diagnostic test kits, announced it has received u.s. food and drug administration (fda) emergency use authorization (eua) of its reebov™ antigen rapid test. the test is to be used for the presumptive detection of ebola zaire virus (detected in the west africa outbreak in 2014) in individuals with signs and symptoms of ebola virus infection in conjunction and with epidemiological risk factors (including geographic locations with high prevalence of ebola infection.) the corgenix ebola rapid test is the first rapid diagnostic test (rdt) and the first immunoassay authorized for emergency use by the fda for the presumptive detection of ebola virus...
2014-12-24 09:15:00 - Press Release
Corgenix Announces New Grants To Advance Work On Ebola Test Kit
Denver--(business wire)--corgenix medical corporation (otcqb: conx.ob), a worldwide developer and marketer of diagnostic test kits, has been awarded two grants totaling $818,000 to advance the development of an ebola rapid diagnostic test kit. the grants were awarded to corgenix by the bill & melinda gates foundation and the paul g. allen family foundation. corgenix has selected three subcontractors to assist on the project: tulane university, autoimmune technologies, llc and zalgen labs, llc. “the scope and seriousness of ebola virus outbreaks have resulted in an increased urgency to bring testing and products to market as soon as possible,” said douglass simpson, corgenix president and ceo...